Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A case cohort study
Version of Record online: 31 JUL 2008
© 2008 The Authors. Journal compilation © 2008 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 23, Issue 8pt1, pages 1259–1266, August 2008
How to Cite
Carr, B. I., Buch, S. C., Kondragunta, V., Pancoska, P. and Branch, R. A. (2008), Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A case cohort study. Journal of Gastroenterology and Hepatology, 23: 1259–1266. doi: 10.1111/j.1440-1746.2008.05487.x
- Issue online: 31 JUL 2008
- Version of Record online: 31 JUL 2008
- Accepted for publication 2 March 2008.
- hepatocellular carcinoma;
- transhepatic arterial chemo-embolization (TACE);
Background and Aims: A total of 967 patients with unresectable and untransplantable, biopsy-proven hepatocellular carcinoma (HCC) were prospectively evaluated at baseline and followed up till death.
Methods: Survival was the end-point for all analyses.
Results: We found in our overall analysis, that male gender, ascites, cirrhosis, portal vein thrombosis (PVT), elevated alpha-fetoprotein (AFP) or bilirubin or alkaline phosphatases were each statistically significant adverse prognostic factors. Patients with normal AFP survived longer than those with elevated AFP, in the presence of PVT, large or bilobar tumors or cirrhosis. We used a bivariate analysis to separate patient subgroups based on poor liver function and aggressive tumor characteristics. In subgroup analysis based on these subsets, there was clear discrimination in survival between subsets; in addition both cirrhosis and presence of PVT were significant, independent but modest risk factors. The results of this large dataset show that amongst nonsurgical HCC patients, there are clear subsets with longer survival than other subsets.
Conclusions: This data also supports the concept of heterogeneity of HCC.